Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 234

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 7
Chunk 234
---
 as a holder of at least 5% of our issued and outstanding share capital), ARK Investment Management LLC, or ARK, (from 6.01% to 0%), based on Form 13F-HR as filed by ARK on January 24, 2023.
 
The information above regarding changes in percentage ownership by major shareholders during the years ended December 31, 2022 through 2024 is based solely on information contained in Schedule 13Gs and Form 13F (as may be amended) as filed by such persons with the SEC.
 

Record Holders
 
 As of March 20, 2025, there are three shareholders of record of our ordinary shares, two of which are located in the United States and one that is located in Israel. The majority of our issued and outstanding ordinary shares were held of record in the United States, in the name of a single record shareholder — Cede & Co., as nominee for the Depository Trust Company. The number of record holders is not representative of the number of beneficial holders of our ordinary shares, nor is it representative of where such beneficial holders reside, since the shares held in the name of Cede & Co. are listed for trading on Nasdaq and the TASE and are beneficially owned by a wide range of underlying beneficial shareholders who hold their shares in “street name,” including Israeli and other non-U.S. shareholders.
B.          Related Party Transactions
 
Except as described below or elsewhere in this Annual Report, since January 1, 2024, we have had no transaction, nor do we have any presently proposed transaction, and neither we nor our subsidiaries have had any loan, nor do we or our subsidiaries have any presently proposed loan, involving any related party described in Item 7.B. of this Annual Report.
 
Agreements with Directors and Officers
 
Employment Agreements
 
We have entered into written employment agreements with all of our executive officers. Each of these agreements contains provisions regarding non-competition, confidentiality of information and assignment of inventions. The non-competition provision applies for a period that is generally 12 months following termination of employment. The enforceability of covenants not to compete in Israel and in the United States is subject to limitations.
Equity Awards
 
See “Item 6. Directors, Senior Management and Employee—B. Compensation—Share Option and Incentive Plans.”
 
Indemnification Agreements
 
Our articles of association allow us to indemnify and insure our office holders for any liability imposed